Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP3K14 | Q99558 | 1/20 | 0.39 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 3/20 | 0.34 |
| ▸ | BRD4 | O60885 | 2/20 | 0.34 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.33 |
| ▸ | HTR2C | P28335 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | DAO | P14920 | 1/20 | 0.31 |
| ▸ | AR | P10275 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10692671 | 0.80 | PARP1 (0.32) | PARP1 | |
| SCHEMBL7727599 | 0.76 | MAP3K14 (0.40) | MAP3K14CREBBPBRD4ACHEALDH1A1 | |
| SCHEMBL31500920 | 0.76 | MAP3K14 (0.40) | MAP3K14CREBBPBRD4ACHEALDH1A1 | |
| SCHEMBL30613493 | 0.73 | PARP1 (0.42) | PARP1CREBBPBRD4 | |
| SCHEMBL6493919 | 0.73 | PARP1 (0.42) | PARP1CREBBPBRD4 | |
| SCHEMBL30363562 | 0.73 | MAP3K14 (0.35) | MAP3K14 | |
| SCHEMBL24112741 | 0.69 | CREBBP (0.47) | PARP1CREBBPBRD4PBRM1HTR2C | |
| SCHEMBL24112853 | 0.69 | CREBBP (0.47) | PARP1CREBBPBRD4PBRM1HTR2C | |
| SCHEMBL9397418 | 0.68 | MAP3K14 (0.40) | MAP3K14HTR2CALDH1A1 | |
| SCHEMBL3238451 | 0.67 | PGR (0.31) | PARP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-4778792-A | Use of 7-acyl benzoxazinones and their derivatives in treating atheromatous disorders | LABORATORIES NEGMA (FR) | 1988-10-18 | — | — | US | disclosed |